Alberta Investment Management Corp Sells 1,614 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Key Points

• Alberta Investment Management Corp has reduced its stake in Regeneron Pharmaceuticals by 22.7%, now holding 5,486 shares worth approximately $3.48 million after selling 1,614 shares.
• Various hedge funds have adjusted their positions in Regeneron, with some increasing their holdings significantly, including Price T Rowe Associates Inc. which raised their stake by 63.5%.
• Regeneron Pharmaceuticals declared a quarterly dividend of $0.88 per share, representing a 0.6% dividend yield and a low payout ratio of 8.96%.

Alberta Investment Management Corp reduced its stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 22.7% in the first quarter, according to its most recent filing with the SEC. The fund owned 5,486 shares of the biopharmaceutical company's stock after selling 1,614 shares during the period. Alberta Investment Management Corp's holdings in Regeneron Pharmaceuticals were worth $3,479,000 as of its most recent SEC filing.

A number of other hedge funds also recently made changes to their positions in the stock. Capital International Investors lifted its holdings in shares of Regeneron Pharmaceuticals by 41.6% during the 4th quarter. Capital International Investors now owns 4,736,929 shares of the biopharmaceutical company's stock worth $3,373,859,000 after acquiring an additional 1,390,534 shares during the last quarter. Dodge & Cox lifted its holdings in shares of Regeneron Pharmaceuticals by 0.4% during the 4th quarter. Dodge & Cox now owns 2,321,316 shares of the biopharmaceutical company's stock worth $1,653,543,000 after acquiring an additional 9,381 shares during the last quarter. Price T Rowe Associates Inc. MD lifted its holdings in shares of Regeneron Pharmaceuticals by 63.5% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 2,085,447 shares of the biopharmaceutical company's stock worth $1,485,527,000 after acquiring an additional 810,144 shares during the last quarter. Northern Trust Corp lifted its holdings in shares of Regeneron Pharmaceuticals by 14.8% during the 4th quarter. Northern Trust Corp now owns 1,054,829 shares of the biopharmaceutical company's stock worth $751,386,000 after acquiring an additional 136,184 shares during the last quarter. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its holdings in shares of Regeneron Pharmaceuticals by 30.1% during the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 982,064 shares of the biopharmaceutical company's stock worth $699,554,000 after acquiring an additional 226,952 shares during the last quarter. 83.31% of the stock is owned by institutional investors.

Regeneron Pharmaceuticals Price Performance

Shares of NASDAQ REGN opened at $558.87 on Friday. Regeneron Pharmaceuticals, Inc. has a 1 year low of $476.49 and a 1 year high of $1,211.20. The company has a debt-to-equity ratio of 0.09, a current ratio of 4.93 and a quick ratio of 4.03. The company's 50-day moving average is $538.05 and its 200 day moving average is $603.39. The stock has a market capitalization of $60.34 billion, a P/E ratio of 14.08, a P/E/G ratio of 2.10 and a beta of 0.33.

Regeneron Pharmaceuticals Announces Dividend

The business also recently declared a quarterly dividend, which was paid on Friday, June 6th. Investors of record on Tuesday, May 20th were given a dividend of $0.88 per share. The ex-dividend date was Tuesday, May 20th. This represents a $3.52 annualized dividend and a dividend yield of 0.6%. Regeneron Pharmaceuticals's payout ratio is currently 8.96%.

Wall Street Analyst Weigh In

REGN has been the subject of a number of research analyst reports. The Goldman Sachs Group dropped their price objective on shares of Regeneron Pharmaceuticals from $917.00 to $804.00 and set a "buy" rating for the company in a report on Wednesday, April 30th. Morgan Stanley reissued an "overweight" rating on shares of Regeneron Pharmaceuticals in a research note on Friday. Wall Street Zen downgraded shares of Regeneron Pharmaceuticals from a "buy" rating to a "hold" rating in a research note on Thursday, May 1st. Robert W. Baird lowered their price target on shares of Regeneron Pharmaceuticals from $759.00 to $652.00 and set a "neutral" rating for the company in a research note on Friday, April 25th. Finally, Cantor Fitzgerald initiated coverage on shares of Regeneron Pharmaceuticals in a research note on Tuesday, April 22nd. They issued an "overweight" rating and a $695.00 price target for the company. One investment analyst has rated the stock with a sell rating, seven have given a hold rating, sixteen have issued a buy rating and two have issued a strong buy rating to the company's stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and an average target price of $837.61.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.